Clinical Manifestations.

Background: First-degree relatives of patients suffering from Alzheimer's Dementia (AD) are at increased risk for developing dementia, yet the associations between family history of AD and cognitive dysfunction remain unclear. Our study aims to understand the intricate interplay between familial risk factors and neurocognitive functioning in AD FDRs versus FDRs of other major psychiatric illnesses by comparing the neuro- cognitive functions of unaffected first-degree relatives (FDR) of patients with AD with unaffected FDR of other major psychiatric illness including Schizophrenia(SCHIZ), Substance use disorders(SUD), Obsessive compulsive disorders(OCD) and Bipolar disorder(BPAD). Subsequently, we also compare the Neuro cognitive performance of FDR's of AD at baseline and after two years longitudinally.

Neurocognitive Functions After 6-Month Buprenorphine (Naloxone)-Based Opioid Agonist Maintenance Treatment: A Controlled Prospective Study.

Background: Medications for opioid use disorder (OUD) may influence neurocognitive functions. Inadequate power, confounders, and practice effects limit the validity of the existing research. We examined the change in cognitive functions in patients with OUD at 6-month buprenorphine (naloxone) posttreatment and compared the cognitive performance of the buprenorphine-treated group with control subjects.

Neurocognitive Dysfunctions in People with Concurrent Cannabis Use and Opioid Dependence: A Cross-Sectional, Controlled Study.

Cannabis and opioid co-dependence is independently associated with cognitive impairments. We examined neurocognitive dysfunctions in people with concurrent opioid dependence with cannabis dependence (OD+CD) or cannabis use (OD+CU) compared to those with only opioid dependence (OD) and healthy controls (HC). We selected adult participants, any sex, who met the diagnosis of OD ( = 268), OD+CU ( = 58), and OD + CD ( = 115).

Effectiveness of buprenorphine (naloxone) for opioid dependence does not differ across opioid categories: a retrospective cohort study from India.

We aimed to examine whether treatment retention, abstinence, and adherence to buprenorphine-naloxone (BNX) differ among individuals with opioid dependence (OD) across three common categories of opioids- heroin, opium, and low-potency pharmaceutical. In a retrospective cohort study, we analyzed outpatient treatment records from March 2020 through February 2022. Opioid category was determined by lifetime and current opioid use.

Heroin use and neuropsychological impairments: comparison of intravenous and inhalational use.

Background And Objectives: Injection and inhalational heroin use are associated with different levels of brain exposure to heroin and its metabolites and differences in the severity of dependence, which might lead to differential impacts on neuropsychological functions. We examined the difference and the magnitude of difference in the neuropsychological functions between inhalational and injection heroin-dependent subjects and also compared them with healthy controls.

Methods: The study sample comprised three groups: 73 subjects with injection heroin dependence, 74 with inhalational heroin dependence, and 75 healthy controls (HC).